NCT00346957

A Phase II Study of Anecortave Acetate for the Treatment of Exudative Age-Related Macular Degeneration

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 128 (actual)
• Sponsor: Alcon Research · Industry
• Sex: All
• Age: 50 Years
• Healthy volunteers: Not accepted

Summary

The purpose of the study is to determine the concentration of anecortave acetate (15 or 30 mg versus placebo) that is safe and effective for the inhibition of the growth of blood vessels in the retina in patients with wet AMD.

Conditions

• AMD

Interventions

Type	Name	Description
DRUG	Anecortave acetate 30 mg	0.5ml administered onto the sclera once every six months for 24 months
DRUG	Anecortave Acetate 15 mg	0.5ml administered onto the sclera once every six months for 24 months
DRUG	Anecortave Acetate 3 mg	0.5ml administered onto the sclera once every six months for 24 months
OTHER	Anecortave Acetate Vehicle	0.5ml administered onto the sclera once every six months for 24 months

Timeline

• Start date: 1999-04-01
• Primary completion: 2003-04-01
• Completion: 2003-04-01
• First posted: 2006-07-04
• Last updated: 2012-03-06